4.8 Article

Mitochondrial mutations drive prostate cancer aggression

Journal

NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-017-00377-y

Keywords

-

Funding

  1. Movember funds through Prostate Cancer Canada
  2. Ontario Institute for Cancer Research - Government of Ontario
  3. Ontario Institute for Cancer Research through Government of Ontario
  4. Princess Margaret Cancer Centre Foundation
  5. Radiation Medicine Program Academic Enrichment Fund
  6. Canadian Cancer Society Research Scientist Award
  7. Prostate Cancer Canada
  8. Movember Foundation [RS2014-01]
  9. Terry Fox Research Institute New Investigator Award
  10. CIHR New Investigator Award
  11. Genome Canada through a Large-Scale Applied Project
  12. German Federal Ministry of Education and Science [FKZ: 01KU1001A, FKZ: 01KU1001-B, FKZ: 01KU1001-C, FKZ: 01KU1001-D]
  13. Arvid Nilsson foundation
  14. Movember funds through Prostate Cancer Canada
  15. Ontario Institute for Cancer Research - Government of Ontario
  16. Ontario Institute for Cancer Research through Government of Ontario
  17. Princess Margaret Cancer Centre Foundation
  18. Radiation Medicine Program Academic Enrichment Fund
  19. Canadian Cancer Society Research Scientist Award
  20. Prostate Cancer Canada
  21. Movember Foundation [RS2014-01]
  22. Terry Fox Research Institute New Investigator Award
  23. CIHR New Investigator Award
  24. Genome Canada through a Large-Scale Applied Project
  25. German Federal Ministry of Education and Science [FKZ: 01KU1001A, FKZ: 01KU1001-B, FKZ: 01KU1001-C, FKZ: 01KU1001-D]
  26. Arvid Nilsson foundation

Ask authors/readers for more resources

Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patients, and identify a median of one mitochondrial single-nucleotide variant (mtSNV) per patient. Some of these mtSNVs occur in recurrent mutational hotspots and associate with aggressive disease. Younger patients have fewer mtSNVs than those who diagnosed at an older age. We demonstrate strong links between mitochondrial and nuclear mutational profiles, with co-occurrence between specific mutations. For example, certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival. These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available